Masa Lasica

First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

John F. Seymour, Chan Y. Cheah, Ricardo Parrondo et al. · Blood · 2023 · 66 citations

Medicine, Hematology, Oncology +14

Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

Sikander Ailawadhi, Zi Chen, Bo Huang et al. · Clinical Cancer Research · 2023 · 38 citations · Full text

Medicine, Oncology, Pharmacology +17

Nephrotic syndrome as a complication of chronic graft‐versus‐host disease after allogeneic haemopoietic stem cell transplantation

Eric Wong, Masa Lasica, Simon He et al. · Internal Medicine Journal · 2016 · 27 citations

Medicine, Nephrology, Pathology +16

The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia

Masa Lasica, Abbey Willcox, Kate Burbury et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2019 · 25 citations

Medicine, Hematology, Oncology +10

First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).

Sikander Ailawadhi, Asher Chanan‐Khan, Zi Chen et al. · Journal of Clinical Oncology · 2021 · 24 citations

Medicine, Oncology, Pharmacology +6